- InterView
- AlphaGo will lead the development of new drugs
- by Nho, Byung Chul Jul 14, 2020 06:12am
- "The future vision of the Center for AI-based New Drug Development Facilitation is the development of a global first in class drug that combines artificial intelligence and medical data." For Hwa Jong Kim (62 years old, director), the direction of organizational management of the Center for AI-based New Drug Development Facilitation is to
- InterView
- Post-corona KSC academic conference finds answer in hybrid
- by An, Kyung-Jin Jul 8, 2020 05:37am
- The Korean medical academy scene also took a hit from the novel coronavirus (COVID-19). Still not contained COVID-19 pandemic had affected the spring academic conference and other events, which left the academic event coordinators in a tight spot. So what is it like to have an academic conference in the day and age of ‘Post-coronaviru
- InterView
- EASY-ON opens up new opportunity to Xarelto amid COVID-19
- by Eo, Yun-Ho Jun 19, 2020 06:24am
- COVID-19 has brought dramatic changes to our lives. Witnessing these changes, scholars stress the importance of responding and planning for the prospective changes in the post-coronavirus era. And many pharmaceutical companies are also seeking for new changes in business model amid COVID-19 pandemic. For the pharmaceutical industry,
- InterView
- Why is Metformin’s investigation expanded?
- by Lee, Tak-Sun Jun 12, 2020 06:11am
- The "detection of NDMA in metformin preparations" published by the MFDS is different from the previous cases. In particular, the difference is that NDMA was not detected in the raw materials. ertain raw materials were a problem in the case of Valsartan or Nizatidine. And, NDMA was also detected in raw materials in the case of Ranitidine.
- InterView
- From accountant to BUD, a leadership from diverse experience
- by Eo, Yun-Ho May 28, 2020 10:08am
- When seeking for the right people to work with, companies require the qualities of being both outstanding in one specific area and competent in various areas. And as a next step, companies provide diverse experience to a competent employee in specific area to train them as a leader to take control over various areas. Such trend has been
- InterView
- Improvement is urgent for many generic drugs
- by Lee, Tak-Sun May 22, 2020 06:16am
- After the Regulatory Reform Committee recommended the withdrawal of the joint bioequivalence test restriction policy in April, the Ministry of Food and Drug Safety's first reaction was to respect the recommendation to withdraw, but said that there was still a problem with the issue of generic restructuring. In a briefing with reporters on
- InterView
- I tried to make the KOEDC 'Social butterfly '
- by Lee, Jeong-Hwan May 8, 2020 06:34am
- “The KOEDC (Korea Orphan & Essential Drug Center) is the place where the government and the public need attention more than any other institution. I wanted to increase the utilization of the public by spreading the awareness to the society that it is a place to supply medicines that are essential for the treatment of incurable patients and t
- InterView
- New antibiotics need to be introduced
- by Eo, Yun-Ho Apr 20, 2020 06:32am
- Antibiotic resistance is a global health issue published by the World Health Organization (WHO). Multi-drug-resistant Gram-negative bacteria has increased worldwide and have become a serious problem in recent medical-related infections. In particular, the World Health Organization has designated Carbapenem-resistant Pseudomonas aeruginosa
- InterView
- Law firm's entry into the pharmaceuticals is just beginning
- by Kim, Jin-Gu Mar 30, 2020 06:18am
- The role of law firms has recently grown in the pharmaceutical bio industry. Some process was through law firms. Kim & Chang, Lee & Ko, Yulchon, HMP Law, and LK Partners are expanding their business areas in the healthcare field. The most prominent law firm is Lee & Ko. The overall evaluation is that, in terms of the health care team members,
- InterView
- CEO Cho Jeong Woo “Cenobamate U.S. release is all ready"
- by Lee, Tak-Sun Mar 13, 2020 06:30am
- A new anti-epileptic drug from SK Biopharmaceuticals, cenobamate (U.S. brand name Xcopri), has set a new milestone in the Korean history of pharmaceutical industry history as it independently won an approval by the U.S. Food and Drug Administration (FDA). To this date, a new drug developed in Korea has been licensed out to foreign pharma
